8-K: Cyclerion Partners Medsteer, Advances CYC-126 for TRD

Cyclerion Therapeutics announced a strategic collaboration with Medsteer to enhance its anesthetic delivery platform for CYC-126 in treatment-resistant depression, targeting a Phase 2 study in H2 2026.

Summary

• Cyclerion Therapeutics, Inc. entered into a Collaboration and Option Agreement with Medsteer, SAS on January 3, 2026.
• The agreement grants Cyclerion a non-exclusive, worldwide, royalty-free license to Medsteer's technology for developing an anesthetic delivery system, and an exclusive option for a royalty-bearing license for commercializing licensed products in the "Company Field" (excluding major surgery, intensive care, or medical transport sedation).
• Cyclerion will pay Medsteer a nominal upfront fee, a payment upon option exercise, and up to $3.7 million in development, regulatory, and sales milestones, plus low single-digit royalties on future net sales.
• The companies will jointly develop an anesthetic delivery system, with Cyclerion paying Medsteer daily fees and expenses for its work.
• Cyclerion provided an update on CYC-126, its lead product candidate for treatment-resistant depression (TRD), which is an anesthetic-based investigational therapy using real-time EEG monitoring and algorithm-guided dosing.
• The company aims to initiate a multinational Phase 2 Proof-of-Concept (POC) study for CYC-126 in the second half of 2026, with initial clinical data expected in 2027 and full POC data in 2028.
• The regulatory strategy involves targeting first patient enrollment in Australia in 2026 via the CTN/HREC pathway, while preparing for a potential future U.S. IND submission.
• As of September 30, 2025, Cyclerion had a cash balance of $4.6 million.
• The company expects a $1 million milestone payment in H1 2026 from Akebia Therapeutics upon first-patient-dosed in their Phase 2 study for praliciguat.
• Cyclerion estimates needing an additional $20 million to reach initial POC data in 2027 and $50 million for full POC data in 2028.

Sentiment

Score: 4

Explanation: While the strategic collaboration and progress on CYC-126 are positive developments, the explicit disclosure of 'substantial doubt regarding our ability to continue as a going concern' and the significant capital requirements relative to current cash balance introduce a high level of financial uncertainty and risk, overshadowing the scientific progress.

Positives

• Strategic collaboration with Medsteer, a leader in closed-loop anesthetic delivery, is expected to accelerate development and reduce technical/execution risk for CYC-126.
• Medsteer's technology is supported by extensive clinical validation across 25 clinical settings and over 9,000 patients.
• CYC-126 is a potential first-in-class therapy for treatment-resistant depression, addressing a significant unmet medical need.
• The use of primarily FDA-cleared device components, combined with Medsteer's partnership and an MIT license, supports a capital-efficient path to device build.
• The regulatory strategy targets an expedited review process in Australia (CTN/HREC pathway) for early first patient enrollment in 2026.
• Expected $1 million milestone payment from Akebia Therapeutics in H1 2026 from the praliciguat out-licensing agreement.
• The company continues to leverage legacy sGC assets to generate revenue to fund its neuropsychiatry pipeline.

Negatives

• The company explicitly states "substantial doubt regarding our ability to continue as a going concern" in its forward-looking statements.
• Significant additional capital is required: $20 million for initial POC data in 2027 and $50 million for full POC data in 2028, which is substantially more than the current cash balance of $4.6 million as of September 30, 2025.
• The collaboration agreement involves milestone payments up to $3.7 million and low single-digit royalties to Medsteer, which will impact future profitability.

Risks

• Substantial doubt regarding the company's ability to continue as a going concern.
• Inability to raise additional funding to support operations and development.
• Challenges in enrolling patients in future clinical studies.
• Difficulty in obtaining regulatory approval for product candidates.
• Unanticipated changes to nonclinical or clinical study protocols due to regulatory reasons or unforeseen events, leading to increased costs and delayed development timelines.
• Reliance on third parties to conduct clinical studies and manufacture drug supplies.
• Inability to adequately protect intellectual property.
• The forward-looking statements may not prove to be accurate, and inaccuracies could be material.

Future Outlook

The company aims to initiate a multinational Phase 2 Proof-of-Concept (POC) study for CYC-126 in the second half of 2026, with initial clinical data anticipated in 2027 and full POC data in 2028. This development is supported by the strategic collaboration with Medsteer, which is expected to accelerate the development of a fit-for-purpose drug delivery system. The regulatory strategy includes targeting first patient enrollment in Australia in 2026 for expedited review, alongside preparatory work for a potential future U.S. IND submission. The company also expects a $1 million milestone payment in the first half of 2026 from an out-licensed asset. However, significant additional capital of $20 million for initial data and $50 million for full data is required, and the company acknowledges substantial doubt about its ability to continue as a going concern without further funding.

Management Comments

• "This strategic collaboration with Medsteer marks an important step in advancing our lead program, CYC-126, a potential first-in-class therapy for treatment-resistant depression." Regina Graul, Ph.D., CEO of Cyclerion.
• "Medsteer’s deep translational expertise and proven closed-loop anesthetic delivery technology make them an ideal strategic partner to accelerate our anesthesia-enabled platform development while potentially reducing technical and execution risk." Regina Graul, Ph.D., CEO of Cyclerion.
• "By combining Cyclerion’s neuropsychiatric and clinical development expertise with Medsteer’s leadership in closed-loop anesthetic delivery systems, we are strengthening our development strategy, reinforcing our clinical timeline, and moving forward with confidence toward initiating our Phase 2 proof-of-concept study in 2026." Regina Graul, Ph.D., CEO of Cyclerion.
• "Treatment-resistant depression remains one of the most pressing unmet needs in mental health. With the continued guidance of our leading scientific advisors, we believe CYC-126 represents a compelling opportunity to deliver a more individualized, technology-enabled approach for patients who are looking for different treatment options." Regina Graul, Ph.D., CEO of Cyclerion.
• "Integrating intelligent software agents with real-time patient feedback holds great potential to improve clinical outcomes. We are thrilled to ramp up our work with Cyclerion Therapeutics in the field of neuropsychiatry and leverage our proprietary algorithms to help build the next generation of therapies." Nicolas Choussat, co-founder and Chief Operating Officer of Medsteer.

Industry Context

This announcement positions Cyclerion at the intersection of neuropsychiatric therapies and advanced medical device technology, specifically in anesthetic delivery systems. The collaboration with Medsteer, a leader in closed-loop anesthetic delivery, aims to integrate real-time patient feedback and EEG monitoring into CYC-126, a novel anesthetic-based therapy for treatment-resistant depression (TRD). This approach seeks to differentiate CYC-126 from existing TRD treatments like Spravato, rTMS, and ECT by offering a more individualized, precision-delivered method. The focus on TRD addresses a significant unmet need, as current treatments often have slow onset or limited efficacy for a substantial portion of patients. The use of AI-based algorithms and closed-loop systems reflects a broader industry trend towards personalized medicine and technology-enhanced therapeutics to optimize patient outcomes.

Comparison to Industry Standards

• CYC-126 aims to be a differentiated treatment for over 3 million patients with TRD, where less than 10% are currently treated with approved therapies like Spravato (35K patients in 2024), rTMS (44K patients in 2023), and ECT (100K patients in 2024).
• The approach leverages generic IV anesthetics (propofol + dexmedetomidine) with extensive clinical safety experience, aiming to de-risk therapeutic use for TRD, building on three early-phase clinical studies that showed propofol's potential as a rapid-acting antidepressant.
• Medsteer's EasyTIVA regulation algorithm has been clinically validated through more than 25 clinical settings and over 9,000 patients, providing a strong foundation for the closed-loop anesthetic delivery system.
• The company's strategy to initiate the Phase 2 POC study in Australia under the CTN/HREC pathway is a common industry practice for expedited clinical trial initiation, allowing for earlier first patient enrollment compared to potentially longer U.S. IND processes.

Stakeholder Impact

• Shareholders: Potential for significant dilution if capital is raised through equity. High risk due to "going concern" warning. Potential long-term value if CYC-126 succeeds, but immediate uncertainty.
• Employees: Uncertainty regarding job security due to "going concern" warning. Potential for growth and innovation if funding is secured and development progresses.
• Customers (Future Patients): Potential for a novel, individualized treatment option for treatment-resistant depression, addressing a high unmet medical need.
• Suppliers/Partners (Medsteer): Medsteer stands to receive milestone payments and royalties, benefiting from the collaboration. However, Cyclerion's financial stability could impact the long-term viability of the partnership.
• Creditors: Increased risk due to the "going concern" warning and significant capital needs.

Next Steps

• Complete device integration and finalize the proprietary drug delivery system for CYC-126.
• Prepare for and receive Pre-IND feedback from the FDA in Q1 2026.
• Receive $1 million milestone payment from Akebia Therapeutics in H1 2026.
• File CTN and receive HREC approval in Australia.
• Initiate multinational Phase 2 Proof-of-Concept (POC) study for CYC-126 in Australia in H2 2026.
• Obtain initial POC clinical data in 2027.
• Obtain full POC clinical data in 2028.
• Prepare for an end-of-Phase 2 meeting.
• Plan for pivotal studies.
• Explore pipeline expansion opportunities.
• Continue diligence with other parties for olinciguat to generate non-dilutive capital.

Key Dates

Recommendation

The explicit disclosure of "substantial doubt regarding our ability to continue as a going concern" is a severe warning sign for investors. Despite the promising scientific developments and strategic partnership, the company's precarious financial position, requiring significant capital raises far exceeding its current cash, indicates a high probability of severe dilution or even bankruptcy. A seasoned investor would prioritize the going concern risk over early-stage clinical progress, leading to a strong sell recommendation.

Keywords

Cyclerion Therapeutics, Medsteer, CYC-126, Treatment-Resistant Depression, TRD, Anesthetic Delivery System, Neuropsychiatry, Biopharmaceutical, Clinical Trial, Phase 2, EEG-guided, Drug-device combination, Collaboration Agreement, Option Agreement, Going Concern, Capital Raise